LexDanaLexDanabeta
Inventor

Christophe Bonny

Inventor
Lausanne, CH

Overview

27→
Patents
1999–2019
Patent span
Human necessities
Primary field (CPC A)

Patents· 27 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides31%
A61KPreparations for medical, dental or toiletry purposes29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
Y02ATechnologies for adaptation to climate change7%
C12NMicroorganisms or enzymes4%
G01NInvestigating or analysing materials by determining their chemical or physical properties2%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
10,174,078Keratan sulfate specific transporter molecules201910,131,690C6S specific transporter molecules201810,023,615Efficient transport into white blood cells20189,688,723'C4S proteoglycan specific transporter molecules'20179,624,267'JNK inhibitor molecules'20179,610,330'Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases'20179,290,538'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20169,180,159'Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases'20159,006,185'Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases'20158,981,052'JNK inhibitor molecules'20158,748,395'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20148,569,447'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20138,278,413'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20128,236,924'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20128,183,339'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20128,080,517'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20117,943,574'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20117,803,749'Peptide inhibitors of MKK7 kinase binding to insulin binding proteins'20107,635,681'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20097,538,091'Intracellular delivery of biological effectors'20097,033,597'Intracellular delivery of biological effectors'20067,034,109'Intracellular delivery of biological effectors'20066,960,648'Intracellular delivery of biological effectors'20056,780,970'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20046,620,914'Transcription factor islet-brain 1 (IB1)'20036,610,820'Cell-permeable peptide inhibitors of the JNK signal transduction pathway'20035,880,261'Transcription factor Islet-Brain 1 (IB1)'1999

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1999–2003Based in Geneva, CH· patent location history
2003–2006Patents assigned to UNIV LAUSANNE (4)· patent assignee history
2003–2011Based in Morges, CH· patent location history
2005–2018Based in Lausanne, CH· patent location history
2006–2018Patents assigned to BONNY CHRISTOPHE (11)· patent assignee history
2009–2013Patents assigned to XIGEN SA (9)· patent assignee history
2014–2018Patents assigned to XIGEN INFLAMMATION LTD (8)· patent assignee history
2017–2019Patents assigned to PHI PHARMA SA (3)· patent assignee history
2017–2019Based in Avenches, CH· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
BONNY CHRISTOPHEself112006–2018
XIGEN SA92009–2013
XIGEN INFLAMMATION LTD82014–2018
UNIV LAUSANNE42003–2006
PHI PHARMA SA32017–2019
Locations
LocationPatentsSpan
Lausanne, CH162005–2018
Morges, CH62003–2011
Avenches, CH32017–2019
Geneva, CH21999–2003